

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
24 March 2022 (24.03.2022)



(10) International Publication Number  
**WO 2022/059766 A1**

(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/13 (2006.01)

(21) International Application Number:

PCT/JP2021/034240

(22) International Filing Date:

17 September 2021 (17.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2020-157873 18 September 2020 (18.09.2020) JP

(71) Applicant: **CHUGAI SEIYAKU KABUSHIKI KAISHA**  
[JP/JP]; 5-1, Ukima 5-chome, Kita-ku, Tokyo, 1158543  
(JP).

(72) Inventors: **IKAWA, Yuri**; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). **OKURA, Yuu**; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 200, Kajiwarra, Kamakura-shi, Kanagawa, 2478530 (JP). **MIZOROKI, Akihiko**; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 200, Kajiwarra, Kamakura-shi, Kanagawa, 2478530 (JP).

(74) Agent: **HARUNA, Masao** et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroschi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-HLA-DQ2.5 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE

(57) Abstract: The present invention relates to anti-HLA-DQ2.5 antibodies and its use for the treatment of celiac disease. The present invention provides anti-HLA-DQ2.5 antibodies that have been modified. The anti-HLA-DQ2.5 antibodies of the invention have binding activity to complexes formed by HLA-DQ2.5 and a gluten peptide, but have substantially no binding activity to complexes formed by HLA-DQ2.5 and an irrelevant peptide. Furthermore, the antibodies of the invention are shown to have inhibitory effects on T cell activation by gluten peptides.

WO 2022/059766 A1